Recently, Suzhou Proton Bio-Pharmaceutical Co., Ltd. (Proton Bio) announced the completion of the B round of financing, with a total financing of 520 million yuan. This round of financing was led by China Merchants Health, China Merchants Capital, China Merchants Securities Investment, Rehabilitation Capital, Guangdong Minsheng Investment Fund, SDIC Taikang Trust Co-investment, the original shareholders SDIC China Merchants, Huimei Capital, Huashan Ruilian Timely Venture Capital Continue to code. This round of financing will further promote the globalization of Proton Bio, accelerate the construction and operation of commercial production bases, and accelerate the improvement of the end-to-end gene and cell therapy (GCT) CDMO platform.
Proton Bio focuses on gene and cell therapy CDMO services, and has quickly built a CDMO platform integrating plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and live bacteria therapy. The 4,000-square-meter R&D and production base is in steady operation. Up to now, it has signed strategic cooperation with many customers and successfully delivered multiple batches of plasmid, virus and cell therapy projects. The large-scale industrialization base of 16,000 square meters will also be put into use in the fourth quarter of this year. At that time, Proton Bio will have a gene and cell therapy process development and production workshop with a total area of more than 20,000 square meters, 10 GMP virus vector production lines, 10 There are GMP cell therapy production lines and hundreds of clean workshops. Proton Bio said that it will continue to strengthen the construction of AAV, oncolytic virus and mRNA platform capabilities, comprehensively increase the production capacity of GMP plasmids, viruses and cell therapy products, and empower the GCT industry.
This round of financing will support Porton Bio to further develop and improve domestic and overseas capacity building and production capacity layout, accelerate the construction of a global, end-to-end gene and cell therapy CDMO platform, and assist in the development and industrial transformation of new gene and cell therapy drugs.
Dr. Wang Yangzhou, CEO of Proton Bio, said, “I am very grateful to China Merchants Health and other new and old strategic investors for their high recognition and trust in Proton Bio. With an excellent talent team, unique technical advantages, complete production lines and service facilities, As well as the advantages of the parent company Proton Co., Ltd.’s many years of successful experience, Proton Bio will work with customers and partners to achieve more milestones in the field of gene and cell therapy. In the future, we will continue to improve and optimize the company’s management system. The ability to develop domestic and foreign markets, with an open, innovative and quality-reliable platform system, provide global customers with excellent CDMO services, so that good medicine can benefit the public earlier.”
China Merchants Health, a representative of investment institutions and the lead investor in this round, said, “From a development perspective, the field of cell and gene therapy has great potential for future development. Proton Bio is a leading cell and gene therapy CDMO service provider in China, with a team of experienced, international China Merchants Health is very pleased to participate in this round of financing of Proton Bio, and looks forward to working with Proton Bio to develop domestic and foreign markets, serve global cell and gene therapy companies, and jointly promote the development of the cell and gene therapy industry for the benefit of more many patients.”
Note: The specific financing amount is provided by the investor or enterprise, and Dottech does not make any endorsement.
media coverage
Venture Capital Technology in the investment world
This article is reprinted from: https://readhub.cn/topic/8iGeGb16z0U
This site is for inclusion only, and the copyright belongs to the original author.